Cancer Biomarkers Market (By Type: Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Others; By Biomolecule; By Application; By Profiling Technology; By End User)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global cancer biomarkers market was valued at USD 15.68 billion in 2023 and it is predicted to surpass around USD 61.37 billion by 2033 with a CAGR of 14.62% from 2024 to 2033.

Cancer Biomarkers Market Size 2024 to 2033

Key Pointers

  • North America led the market with the largest market share in 2023.
  • Asia-Pacific is poised to exhibit the most rapid growth from 2024 to 2033.
  • By Type, the breast cancer segment held the largest revenue share in 2023.
  • By Application, the diagnostics segment emerged as the dominant force in the cancer biomarkers market.
  • By Application, the personalized medicine segment stands out as the fastest-growing segment in the forecast period.
  • By Biomolecule, the genetic biomarkers segment emerged as the dominant force in the cancer biomarkers market.
  • By Biomolecule, the epigenetics segment stands out as the fastest-growing segment from 2024 to 2033.

Cancer Biomarkers Market Growth Factors

The growth of the cancer biomarkers market is underpinned by a multitude of factors driving its expansion. Firstly, the escalating global burden of cancer, coupled with the imperative for early detection and personalized treatment strategies, fuels the demand for innovative biomarker-based solutions. Additionally, advancements in omics technologies, such as genomics, proteomics, and metabolomics, empower researchers to identify novel biomarkers with enhanced specificity and sensitivity. Moreover, the burgeoning interest in precision medicine, characterized by tailored therapeutic interventions based on individual patient profiles, amplifies the relevance of biomarker-driven approaches in clinical practice. Furthermore, strategic collaborations between industry players, academic institutions, and regulatory agencies facilitate the translation of biomarker discoveries into clinically actionable tools. Lastly, the advent of digital health technologies, including artificial intelligence and machine learning, streamlines biomarker discovery processes and enhances diagnostic accuracy, further propelling market growth.

Cancer Biomarkers Market Trends:

  • Advancements in Omics Technologies: Continuous innovation in genomics, proteomics, metabolomics, and other omics disciplines facilitates the discovery of novel cancer biomarkers with enhanced specificity and sensitivity.
  • Rise of Liquid Biopsy Approaches: Liquid biopsy techniques, enabling the non-invasive detection of circulating tumor DNA, circulating tumor cells, and other biomarkers from bodily fluids, gain prominence for their potential in early cancer detection, treatment monitoring, and prognostication.
  • Integration of Artificial Intelligence (AI) and Machine Learning (ML): The incorporation of AI and ML algorithms accelerates biomarker discovery, enhances diagnostic accuracy, and enables personalized treatment recommendations based on complex data analyses.
  • Focus on Immunotherapy Biomarkers: With the growing adoption of immunotherapy in cancer treatment, there is an increased emphasis on identifying predictive biomarkers, such as PD-L1 expression levels and tumor mutational burden, to guide patient selection and treatment response assessment.
  • Development of Multiplex Biomarker Assays: Multiplex biomarker assays, capable of simultaneously measuring multiple biomarkers from a single sample, emerge as valuable tools for comprehensive molecular profiling and personalized treatment decision-making.
  • Expansion of Companion Diagnostics: The expanding repertoire of targeted therapies necessitates the development of companion diagnostics to identify patients who are most likely to benefit from specific treatments, thereby optimizing therapeutic outcomes and minimizing adverse effects.
  • Growing Role of Liquid Biopsy in Clinical Trials: Liquid biopsy assays gain traction in clinical trial settings for their potential to provide real-time monitoring of treatment response, detect minimal residual disease, and uncover mechanisms of therapeutic resistance.

Type Insights

In 2023, the breast cancer segment asserted its dominance in the cancer biomarkers market. As reported by the World Health Organization (WHO), breast cancer afflicted 2.3 million women globally in 2020, resulting in 685,000 fatalities. By the end of 2020, breast cancer had been diagnosed in 7.8 million women over the preceding five years, solidifying its status as the most prevalent cancer worldwide. Consequently, the increasing incidence of breast cancer is a key driver propelling the growth of this segment.

Meanwhile, the lung cancer segment emerged as the fastest-growing segment within the cancer biomarkers market in 2023. Lung cancer predominantly affects the elderly population, with the majority of diagnoses occurring in individuals aged 65 and above. Only a small fraction of those diagnosed are under 45 years old, and the average age at diagnosis typically hovers around 70 years. Thus, the expanding geriatric population stands as a significant factor fueling the growth of this segment.

Application Insights

In 2023, the diagnostics segment emerged as the dominant force in the cancer biomarkers market. This dominance is fueled by several factors, including the increasing development of cancer biomarkers through oncology tests boasting high efficiency and effectiveness, as well as growing government initiatives. These elements collectively contribute to the segment's growth trajectory during the forecast period.

The personalized medicine segment stands out as the fastest-growing segment in the forecast period. This growth is propelled by rising awareness among healthcare practitioners regarding cancer biomarkers and the surging demand for personalized medicines. Moreover, the ease of obtaining approvals for diagnostic tests nowadays is a significant factor propelling the growth of this segment, further amplifying the demand for cancer biomarkers.

Biomolecule Insights

In 2023, the genetic biomarkers segment emerged as the dominant force in the cancer biomarkers market. These biomarkers are widely utilized due to their high efficiency and effectiveness, making them indispensable for the diagnosis and treatment of cancer. Consequently, the extensive usage and efficacy of genetic biomarkers are key drivers propelling the growth of this segment.

The epigenetics segment stands out as the fastest-growing segment over the forecast period. This growth is fueled by increasing research efforts aimed at developing novel biomarkers within the field of epigenetics. Additionally, collaborations between market players and pharmaceutical firms are further bolstering the growth of this segment, contributing to its rapid expansion.

Regional Insights

In 2023, North America emerged as the leading force in the cancer biomarkers market. Within the North American region, the United States held sway over the market, boasting a substantial share. This dominance is attributed to the presence of a plethora of market players dedicated to the cancer biomarkers sector. Moreover, the U.S. government's substantial investments in research and development endeavors aimed at fostering novel product development contribute significantly to the region's dominance. Additionally, the adoption of innovative and advanced technologies further propels the growth of the cancer biomarkers market in North America.

Cancer Biomarkers Market Share, By Region, 2023 (%)

Asia-Pacific is poised to exhibit the most rapid growth during the forecast period. The expansion of the cancer biomarkers market in the Asia-Pacific region is fueled by the escalating prevalence of cancer, driving the demand for effective diagnostic and treatment solutions. Furthermore, continuous government funding for development activities aimed at introducing new products augments the region's growth trajectory. Additionally, the increasing awareness regarding cancer biomarkers among healthcare professionals and the general populace contributes to the market's growth in the Asia-Pacific region.

Cancer Biomarkers Market Key Companies

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina Inc.
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Exact Sciences
  • Meso Scale Diagnostics LLC
  • Seegene Technologies Inc.
  • Siemens Healthineers

Cancer Biomarkers Market Segmentations:

By Type

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Others

By Biomolecule

  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Others

By Application

  • Drug Discovery and Development
  • Diagnostics
  • Personalized Medicine
  • Others

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics-based Tests

By End User

  • Hospitals
  • Academic and Cancer Research Institutes
  • Ambulatory Surgical Centres
  • Diagnostic Laboratories

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global cancer biomarkers market size was reached at USD 15.68 billion in 2023 and it is projected to hit around USD 61.37 billion by 2033.

The global cancer biomarkers market is growing at a compound annual growth rate (CAGR) of 14.62% from 2024 to 2033.

The North America region has accounted for the largest cancer biomarkers market share in 2023.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Biomarkers Market 

5.1. COVID-19 Landscape: Cancer Biomarkers Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Biomarkers Market, By Type

8.1. Cancer Biomarkers Market, by Type, 2024-2033

8.1.1. Breast Cancer

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Prostate Cancer

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Liver Cancer

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Lung Cancer

8.1.6.1. Market Revenue and Forecast (2021-2033)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Cancer Biomarkers Market, By Biomolecule

9.1. Cancer Biomarkers Market, by Biomolecule, 2024-2033

9.1.1. Genetic Biomarkers

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Epigenetic Biomarkers

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Metabolic Biomarkers

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Proteomic Biomarkers

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Cancer Biomarkers Market, By Application 

10.1. Cancer Biomarkers Market, by Application, 2024-2033

10.1.1. Drug Discovery and Development

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Diagnostics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Personalized Medicine

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Cancer Biomarkers Market, By Profiling Technology

11.1. Cancer Biomarkers Market, by Profiling Technology, 2024-2033

11.1.1. Omic Technologies

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Imaging Technologies

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Immunoassays

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Cytogenetics-based Tests

11.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Cancer Biomarkers Market, By End User

12.1. Cancer Biomarkers Market, by End User, 2024-2033

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Academic and Cancer Research Institutes

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Ambulatory Surgical Centres

12.1.3.1. Market Revenue and Forecast (2021-2033)

12.1.4. Diagnostic Laboratories

12.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Cancer Biomarkers Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type (2021-2033)

13.1.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.1.3. Market Revenue and Forecast, by Application (2021-2033)

13.1.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.1.5. Market Revenue and Forecast, by End User (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.1.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.1.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.1.7. Market Revenue and Forecast, by End User (2021-2033) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Type (2021-2033)

13.1.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.1.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.1.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.1.8.5. Market Revenue and Forecast, by End User (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type (2021-2033)

13.2.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.2.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.4. Market Revenue and Forecast, by Profiling Technology (2021-2033) 

13.2.5. Market Revenue and Forecast, by End User (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.2.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.7. Market Revenue and Forecast, by Profiling Technology (2021-2033) 

13.2.8. Market Revenue and Forecast, by End User (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.2.9.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.10. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.2.11. Market Revenue and Forecast, by End User (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.2.12.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.12.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.2.13. Market Revenue and Forecast, by End User (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.2.14.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.14.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.2.15. Market Revenue and Forecast, by End User (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type (2021-2033)

13.3.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.3.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.3.5. Market Revenue and Forecast, by End User (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.3.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.3.7. Market Revenue and Forecast, by End User (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.3.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.3.9. Market Revenue and Forecast, by End User (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.3.10.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.10.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.3.10.5. Market Revenue and Forecast, by End User (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.3.11.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.11.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.3.11.5. Market Revenue and Forecast, by End User (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type (2021-2033)

13.4.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.4.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.4.5. Market Revenue and Forecast, by End User (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.4.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.4.7. Market Revenue and Forecast, by End User (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.4.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.4.9. Market Revenue and Forecast, by End User (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.4.10.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.10.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.4.10.5. Market Revenue and Forecast, by End User (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.4.11.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.11.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.4.11.5. Market Revenue and Forecast, by End User (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type (2021-2033)

13.5.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.5.3. Market Revenue and Forecast, by Application (2021-2033)

13.5.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.5.5. Market Revenue and Forecast, by End User (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.5.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.5.6.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.5.7. Market Revenue and Forecast, by End User (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Biomolecule (2021-2033)

13.5.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.5.8.4. Market Revenue and Forecast, by Profiling Technology (2021-2033)

13.5.8.5. Market Revenue and Forecast, by End User (2021-2033)

Chapter 14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Thermo Fisher Scientific Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. QIAGEN N.V.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Illumina Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bio-Rad Laboratories Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Abbott Laboratories

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Exact Sciences

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Meso Scale Diagnostics LLC

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Seegene Technologies Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Siemens Healthineers

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert